pair_id int64 | intervention_id int64 | condition_id int64 | smiles string | inchikey string | inchikey_connectivity string | chembl_id string | molecular_type string | intervention_type string | condition_name string | mesh_id string | confidence_tier string | primary_failure_category string | num_trials int64 | num_sources int64 | highest_phase_reached string | intervention_degree int64 | condition_degree int64 | target_count int64 | earliest_completion_year float64 | split_random string | split_cold_drug string | split_cold_condition string | split_temporal string | split_scaffold string | split_degree_balanced string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
189,153 | 3 | 4 | null | null | null | null | null | drug | Healthy Participants | Arbovirus Infections | gold | safety | 12 | 2 | phase_3 | 4,088 | 44 | 0 | 2,012 | train | train | train | train | null | train |
189,154 | 3 | 5 | null | null | null | null | null | drug | Heart Failure | Cardiovascular Diseases | gold | efficacy | 62 | 2 | phase_4 | 4,088 | 185 | 0 | 2,006 | train | train | train | train | null | train |
189,155 | 3 | 6 | null | null | null | null | null | drug | Plaque Psoriasis | null | gold | efficacy | 22 | 1 | phase_4 | 4,088 | 71 | 0 | 2,015 | test | train | train | train | null | train |
189,156 | 3 | 7 | null | null | null | null | null | drug | Bladder Cancer | Carcinoma | gold | efficacy | 8 | 1 | phase_3 | 4,088 | 136 | 0 | 2,011 | train | train | test | train | null | train |
189,157 | 3 | 8 | null | null | null | null | null | drug | Healthy | null | gold | efficacy | 91 | 2 | phase_4 | 4,088 | 457 | 0 | 2,008 | train | train | val | train | null | train |
189,158 | 3 | 10 | null | null | null | null | null | drug | Cardiovascular Disease | Cardiovascular Diseases | gold | efficacy | 22 | 1 | phase_4 | 4,088 | 55 | 0 | 2,007 | test | train | train | train | null | train |
189,159 | 3 | 19 | null | null | null | null | null | drug | Exercise | Behavior | gold | efficacy | 1 | 1 | phase_4 | 4,088 | 3 | 0 | null | train | train | train | train | null | train |
189,160 | 3 | 20 | null | null | null | null | null | drug | Sleep | Behavior | gold | efficacy | 5 | 2 | phase_4 | 4,088 | 19 | 0 | 2,013 | train | train | train | train | null | test |
189,161 | 3 | 21 | null | null | null | null | null | drug | Cicatrix | Cicatrix | copper | other | 1 | 1 | phase_2 | 4,088 | 7 | 0 | 2,022 | train | train | train | test | null | train |
189,162 | 3 | 22 | null | null | null | null | null | drug | Pruritus | Pathological Conditions, Signs and Symptoms | gold | efficacy | 6 | 2 | phase_4 | 4,088 | 34 | 0 | 2,014 | train | train | train | train | null | train |
189,163 | 3 | 24 | null | null | null | null | null | drug | Pulmonary Hypertension | Cardiovascular Diseases | gold | efficacy | 22 | 2 | phase_4 | 4,088 | 64 | 0 | 2,009 | train | train | train | train | null | train |
189,164 | 3 | 25 | null | null | null | null | null | drug | Leukemia | Burkitt Lymphoma | gold | efficacy | 8 | 1 | phase_3 | 4,088 | 260 | 0 | 2,009 | train | train | train | train | null | train |
189,165 | 3 | 26 | null | null | null | null | null | drug | Lymphoma | Burkitt Lymphoma | gold | efficacy | 11 | 1 | phase_3 | 4,088 | 361 | 0 | 2,009 | train | train | train | train | null | train |
189,166 | 3 | 27 | null | null | null | null | null | drug | Epilepsy | Brain Diseases | gold | efficacy | 15 | 2 | phase_4 | 4,088 | 62 | 0 | 2,003 | train | train | train | train | null | train |
189,167 | 3 | 30 | null | null | null | null | null | drug | Adenocarcinoma of the Pancreas | Actinomycetales Infections | bronze | efficacy | 1 | 1 | phase_2 | 4,088 | 17 | 0 | 2,012 | val | train | test | train | null | train |
189,168 | 3 | 31 | null | null | null | null | null | drug | Cognition | Breast Diseases | gold | efficacy | 1 | 1 | phase_4 | 4,088 | 4 | 0 | 2,010 | test | train | train | train | null | train |
189,169 | 3 | 32 | null | null | null | null | null | drug | Aging | Breast Diseases | gold | enrollment | 8 | 1 | phase_3 | 4,088 | 29 | 0 | 2,015 | val | train | train | train | null | train |
189,170 | 3 | 35 | null | null | null | null | null | drug | Ischemia | Arterial Occlusive Diseases | gold | enrollment | 2 | 1 | phase_4 | 4,088 | 11 | 0 | 2,011 | train | train | val | train | null | test |
189,171 | 3 | 36 | null | null | null | null | null | drug | Prostate Cancer | Genital Diseases | gold | efficacy | 27 | 2 | phase_4 | 4,088 | 418 | 0 | 2,004 | test | train | train | train | null | test |
189,172 | 3 | 37 | null | null | null | null | null | drug | Metastatic Colorectal Cancer | Colonic Diseases | gold | efficacy | 9 | 1 | phase_3 | 4,088 | 132 | 0 | 2,010 | train | train | train | train | null | train |
189,173 | 3 | 38 | null | null | null | null | null | drug | Rosacea | Rosacea | gold | efficacy | 2 | 1 | phase_3 | 4,088 | 18 | 0 | 2,008 | test | train | val | train | null | train |
189,174 | 3 | 39 | null | null | null | null | null | drug | Advanced Hepatocellular Carcinoma | Adenocarcinoma | silver | safety | 2 | 1 | phase_2 | 4,088 | 18 | 0 | 2,009 | train | train | test | train | null | train |
189,175 | 3 | 41 | null | null | null | null | null | drug | Bipolar Disorder | Bipolar Disorder | gold | efficacy | 43 | 2 | phase_4 | 4,088 | 102 | 0 | 2,007 | test | train | train | train | null | train |
189,176 | 3 | 43 | null | null | null | null | null | drug | NAFLD | Digestive System Diseases | silver | efficacy | 4 | 1 | phase_2 | 4,088 | 12 | 0 | 2,017 | train | train | train | train | null | train |
189,177 | 3 | 46 | null | null | null | null | null | drug | Pyoderma Gangrenosum | Colitis | bronze | efficacy | 1 | 1 | phase_3 | 4,088 | 7 | 0 | 2,025 | train | train | train | test | null | train |
189,178 | 3 | 47 | null | null | null | null | null | drug | Crohn's Disease | Colitis | gold | efficacy | 46 | 2 | phase_4 | 4,088 | 141 | 0 | 2,008 | train | train | train | train | null | train |
189,179 | 3 | 48 | null | null | null | null | null | drug | Ulcerative Colitis | Colitis | gold | efficacy | 61 | 2 | phase_4 | 4,088 | 168 | 0 | 2,009 | test | train | train | train | null | train |
189,180 | 3 | 49 | null | null | null | null | null | drug | Inflammatory Bowel Disease | Colitis | bronze | enrollment | 4 | 2 | phase_3 | 4,088 | 21 | 0 | 2,014 | train | train | train | train | null | train |
189,181 | 3 | 50 | null | null | null | null | null | drug | HIV Infections | Blood-Borne Infections | gold | efficacy | 38 | 2 | phase_4 | 4,088 | 368 | 0 | 1,996 | test | train | test | train | null | train |
189,182 | 3 | 51 | null | null | null | null | null | drug | Healthy Volunteer | null | copper | other | 3 | 1 | phase_1 | 4,088 | 14 | 0 | 2,020 | val | train | test | test | null | train |
189,183 | 3 | 52 | null | null | null | null | null | drug | Myeloma | Blood Protein Disorders | silver | efficacy | 1 | 1 | phase_2 | 4,088 | 53 | 0 | 2,022 | train | train | test | test | null | test |
189,184 | 3 | 53 | null | null | null | null | null | drug | Stem Cell Transplantation | Blood Protein Disorders | bronze | enrollment | 1 | 1 | phase_1_2 | 4,088 | 25 | 0 | 2,011 | train | train | test | train | null | train |
189,185 | 3 | 54 | null | null | null | null | null | drug | Acute Myeloid Leukemia | Hematologic Diseases | gold | efficacy | 7 | 2 | phase_3 | 4,088 | 286 | 0 | 2,017 | train | train | train | train | null | test |
189,186 | 3 | 56 | null | null | null | null | null | drug | Graft vs Host Disease | Graft vs Host Disease | bronze | enrollment | 1 | 1 | phase_2 | 4,088 | 41 | 0 | 2,021 | train | train | train | test | null | train |
189,187 | 3 | 58 | null | null | null | null | null | drug | Pulmonary Disease, Chronic Obstructive | Chronic Disease | gold | efficacy | 51 | 2 | phase_4 | 4,088 | 212 | 0 | 2,008 | train | train | train | train | null | train |
189,188 | 3 | 60 | null | null | null | null | null | drug | Hypertension | Cardiovascular Diseases | gold | efficacy | 44 | 2 | phase_4 | 4,088 | 326 | 0 | 2,006 | train | train | train | train | null | train |
189,189 | 3 | 63 | null | null | null | null | null | drug | Chronic Hepatitis C | Blood-Borne Infections | silver | other | 6 | 2 | phase_3 | 4,088 | 55 | 0 | 2,008 | test | train | test | train | null | test |
189,190 | 3 | 64 | null | null | null | null | null | drug | Schizophrenia | Behavior | gold | efficacy | 97 | 2 | phase_4 | 4,088 | 279 | 0 | 2,007 | test | train | train | train | null | train |
189,191 | 3 | 65 | null | null | null | null | null | drug | Healthy Volunteers | Autoimmune Diseases | gold | other | 46 | 2 | phase_4 | 4,088 | 205 | 0 | 2,008 | train | train | train | train | null | val |
189,192 | 3 | 66 | null | null | null | null | null | drug | Diabetes Mellitus, Type 1 | Autoimmune Diseases | gold | efficacy | 16 | 1 | phase_3 | 4,088 | 113 | 0 | 2,009 | train | train | train | train | null | train |
189,193 | 3 | 67 | null | null | null | null | null | drug | Immune Thrombocytopenia | Autoimmune Diseases | gold | efficacy | 2 | 1 | phase_3 | 4,088 | 8 | 0 | 2,015 | train | train | train | train | null | train |
189,194 | 3 | 68 | null | null | null | null | null | drug | Metastatic Breast Cancer | Breast Diseases | gold | efficacy | 10 | 1 | phase_3 | 4,088 | 142 | 0 | 2,017 | train | train | train | train | null | test |
189,195 | 3 | 70 | null | null | null | null | null | drug | Myelodysplastic Syndromes | Bone Marrow Diseases | gold | efficacy | 16 | 2 | phase_3 | 4,088 | 196 | 0 | 2,010 | test | train | test | train | null | train |
189,196 | 3 | 71 | null | null | null | null | null | drug | Seasonal Allergic Rhinitis | Asthma | gold | efficacy | 18 | 1 | phase_4 | 4,088 | 39 | 0 | 1,993 | train | train | train | train | null | test |
189,197 | 3 | 72 | null | null | null | null | null | drug | Asthma | Asthma | gold | efficacy | 146 | 2 | phase_4 | 4,088 | 589 | 0 | 2,003 | train | train | train | train | null | test |
189,198 | 3 | 73 | null | null | null | null | null | drug | Metastatic Hormone-Sensitive Prostate Cancer | null | gold | efficacy | 2 | 1 | phase_3 | 4,088 | 8 | 0 | 2,023 | test | train | train | test | null | test |
189,199 | 3 | 74 | null | null | null | null | null | drug | Acute Graft Versus Host Disease | Bronchial Diseases | copper | other | 1 | 1 | phase_3 | 4,088 | 10 | 0 | 2,021 | val | train | train | test | null | train |
189,200 | 3 | 75 | null | null | null | null | null | drug | Erectile Dysfunction | Dyslipidemias | gold | efficacy | 7 | 1 | phase_4 | 4,088 | 41 | 0 | 2,008 | train | train | train | train | null | train |
189,201 | 3 | 79 | null | null | null | null | null | drug | Alzheimer's Disease | Alzheimer Disease | gold | efficacy | 78 | 2 | phase_4 | 4,088 | 157 | 0 | 2,007 | test | train | val | train | null | val |
189,202 | 3 | 80 | null | null | null | null | null | drug | Hepatitis C | Blood Protein Disorders | gold | efficacy | 14 | 2 | phase_4 | 4,088 | 105 | 0 | 2,010 | train | train | test | train | null | train |
189,203 | 3 | 81 | null | null | null | null | null | drug | Cryoglobulinemia | Blood Protein Disorders | bronze | enrollment | 1 | 1 | phase_2 | 4,088 | 3 | 0 | 2,018 | test | train | test | val | null | train |
189,204 | 3 | 82 | null | null | null | null | null | drug | Dengue | Arbovirus Infections | silver | efficacy | 3 | 2 | phase_2 | 4,088 | 7 | 0 | 2,020 | test | train | train | test | null | train |
189,205 | 3 | 83 | null | null | null | null | null | drug | Hypersensitivity | Asthma | gold | efficacy | 2 | 1 | phase_3 | 4,088 | 14 | 0 | 2,020 | train | train | train | test | null | train |
189,206 | 3 | 85 | null | null | null | null | null | drug | Lung Cancer | Bronchial Neoplasms | gold | efficacy | 29 | 1 | phase_3 | 4,088 | 250 | 0 | 2,008 | train | train | train | train | null | test |
189,207 | 3 | 88 | null | null | null | null | null | drug | Glucose Metabolism Disorders | Brain Diseases | gold | efficacy | 5 | 2 | phase_4 | 4,088 | 18 | 0 | 2,007 | train | train | train | train | null | train |
189,208 | 3 | 92 | null | null | null | null | null | drug | Xerostomia | Head and Neck Neoplasms | bronze | strategic | 1 | 1 | phase_2 | 4,088 | 12 | 0 | 2,012 | test | train | val | train | null | train |
189,209 | 3 | 95 | null | null | null | null | null | drug | Atrial Fibrillation New Onset | Arrhythmias, Cardiac | bronze | enrollment | 1 | 1 | null | 4,088 | 4 | 0 | 2,015 | test | train | train | train | null | train |
189,210 | 3 | 97 | null | null | null | null | null | drug | COVID-19 | COVID-19 | gold | efficacy | 150 | 2 | phase_4 | 4,088 | 527 | 0 | 2,020 | val | train | train | test | null | train |
189,211 | 3 | 98 | null | null | null | null | null | drug | SARS-CoV 2 | COVID-19 | bronze | other | 5 | 2 | phase_3 | 4,088 | 41 | 0 | 2,020 | test | train | train | test | null | train |
189,212 | 3 | 102 | null | null | null | null | null | drug | Multiple Sclerosis | Autoimmune Diseases | gold | efficacy | 63 | 2 | phase_4 | 4,088 | 172 | 0 | 2,002 | val | train | train | train | null | train |
189,213 | 3 | 103 | null | null | null | null | null | drug | Hepatocellular Carcinoma | Adenocarcinoma | gold | efficacy | 13 | 2 | phase_3 | 4,088 | 179 | 0 | 2,008 | test | train | test | train | null | train |
189,214 | 3 | 104 | null | null | null | null | null | drug | Infertility | Adnexal Diseases | gold | enrollment | 4 | 1 | phase_4 | 4,088 | 99 | 0 | 2,011 | train | train | train | train | null | train |
189,215 | 3 | 107 | null | null | null | null | null | drug | Postoperative Pain | Neurologic Manifestations | gold | efficacy | 15 | 1 | phase_4 | 4,088 | 128 | 0 | 2,008 | train | train | train | train | null | val |
189,216 | 3 | 108 | null | null | null | null | null | drug | Non-Small Cell Lung Cancer | Bronchial Neoplasms | gold | efficacy | 33 | 2 | phase_3 | 4,088 | 317 | 0 | 2,008 | val | train | train | train | null | train |
189,217 | 3 | 111 | null | null | null | null | null | drug | Cerebral Infarction | Brain Diseases | gold | efficacy | 2 | 1 | phase_4 | 4,088 | 8 | 0 | 2,008 | test | train | train | train | null | train |
189,218 | 3 | 113 | null | null | null | null | null | drug | Acute Stroke | Brain Diseases | bronze | other | 3 | 2 | phase_3 | 4,088 | 9 | 0 | 2,012 | train | train | train | train | null | train |
189,219 | 3 | 114 | null | null | null | null | null | drug | Brain Infarction | Brain Diseases | bronze | efficacy | 2 | 1 | phase_3 | 4,088 | 4 | 0 | 2,008 | test | train | train | train | null | train |
189,220 | 3 | 117 | null | null | null | null | null | drug | Constipation | Basal Ganglia Diseases | gold | efficacy | 11 | 1 | phase_4 | 4,088 | 50 | 0 | 2,006 | train | train | train | train | null | train |
189,221 | 3 | 118 | null | null | null | null | null | drug | Parkinson Disease | Basal Ganglia Diseases | gold | efficacy | 29 | 2 | phase_4 | 4,088 | 133 | 0 | 2,008 | val | train | train | train | null | train |
189,222 | 3 | 120 | null | null | null | null | null | drug | Deep Vein Thrombosis | Cardiovascular Diseases | bronze | other | 3 | 1 | phase_4 | 4,088 | 24 | 0 | 2,003 | train | train | train | train | null | val |
189,223 | 3 | 121 | null | null | null | null | null | drug | Pulmonary Embolism | Cardiovascular Diseases | bronze | other | 5 | 2 | phase_4 | 4,088 | 39 | 0 | 2,017 | train | train | train | train | null | train |
189,224 | 3 | 122 | null | null | null | null | null | drug | Traumatic Brain Injury | Brain Damage, Chronic | gold | efficacy | 13 | 2 | phase_4 | 4,088 | 65 | 0 | 2,010 | train | train | train | train | null | train |
189,225 | 3 | 123 | null | null | null | null | null | drug | Diabetes Mellitus | Cardiovascular Diseases | gold | efficacy | 25 | 2 | phase_4 | 4,088 | 170 | 0 | 2,004 | train | train | train | train | null | train |
189,226 | 3 | 124 | null | null | null | null | null | drug | Essential Hypertension | Cardiovascular Diseases | silver | efficacy | 2 | 1 | phase_2_3 | 4,088 | 30 | 0 | 2,017 | train | train | train | train | null | train |
189,227 | 3 | 125 | null | null | null | null | null | drug | Vomiting | Abdominal Pain | gold | efficacy | 6 | 1 | phase_3 | 4,088 | 47 | 0 | 2,010 | test | train | train | train | null | train |
189,228 | 3 | 126 | null | null | null | null | null | drug | Nausea | Abdominal Pain | gold | efficacy | 8 | 1 | phase_4 | 4,088 | 58 | 0 | 2,010 | train | train | train | train | null | val |
189,229 | 3 | 127 | null | null | null | null | null | drug | Abdominal Pain | Abdominal Pain | gold | efficacy | 4 | 1 | phase_3 | 4,088 | 12 | 0 | 2,008 | val | train | train | train | null | val |
189,230 | 3 | 128 | null | null | null | null | null | drug | Cannabis Use | Abdominal Pain | copper | other | 1 | 1 | phase_3 | 4,088 | 3 | 0 | 2,023 | test | train | train | test | null | train |
189,231 | 3 | 129 | null | null | null | null | null | drug | Melanoma | Melanoma | gold | efficacy | 14 | 1 | phase_3 | 4,088 | 265 | 0 | 2,008 | train | train | val | train | null | train |
189,232 | 3 | 133 | null | null | null | null | null | drug | Autoimmune Diseases | Autoimmune Diseases | silver | efficacy | 3 | 2 | phase_4 | 4,088 | 12 | 0 | 2,024 | test | train | train | test | null | train |
189,233 | 3 | 135 | null | null | null | null | null | drug | Acute Myeloid Leukemia (AML) | Hematologic Diseases | gold | efficacy | 2 | 1 | phase_3 | 4,088 | 84 | 0 | 2,024 | train | train | train | test | null | train |
189,234 | 3 | 138 | null | null | null | null | null | drug | IgA Nephropathy | Autoimmune Diseases | silver | other | 4 | 2 | phase_3 | 4,088 | 19 | 0 | 2,018 | train | train | train | val | null | train |
189,235 | 3 | 140 | null | null | null | null | null | drug | Menopause | Anxiety Disorders | gold | efficacy | 19 | 2 | phase_4 | 4,088 | 45 | 0 | 2,006 | train | train | train | train | null | train |
189,236 | 3 | 141 | null | null | null | null | null | drug | Perimenopause | Anxiety Disorders | silver | efficacy | 1 | 1 | phase_1_2 | 4,088 | 2 | 0 | 2,024 | train | train | train | test | null | train |
189,237 | 3 | 142 | null | null | null | null | null | drug | Generalized Myasthenia Gravis | Autoimmune Diseases | gold | efficacy | 5 | 2 | phase_3 | 4,088 | 9 | 0 | 2,020 | val | train | train | test | null | train |
189,238 | 3 | 143 | null | null | null | null | null | drug | Type 1 Diabetes Mellitus | Autoimmune Diseases | gold | efficacy | 15 | 1 | phase_3 | 4,088 | 86 | 0 | 2,011 | train | train | train | train | null | train |
189,239 | 3 | 144 | null | null | null | null | null | drug | T1D | Autoimmune Diseases | silver | efficacy | 1 | 1 | phase_2 | 4,088 | 3 | 0 | 2,020 | train | train | train | test | null | train |
189,240 | 3 | 145 | null | null | null | null | null | drug | T1DM | Autoimmune Diseases | silver | efficacy | 1 | 1 | phase_2 | 4,088 | 3 | 0 | 2,020 | train | train | train | test | null | train |
189,241 | 3 | 150 | null | null | null | null | null | drug | Type 1 Diabetes | Autoimmune Diseases | gold | efficacy | 13 | 1 | phase_4 | 4,088 | 86 | 0 | 2,010 | train | train | train | train | null | train |
189,242 | 3 | 153 | null | null | null | null | null | drug | Clostridium Difficile | Bacterial Infections | gold | enrollment | 4 | 1 | phase_4 | 4,088 | 16 | 0 | 2,012 | train | train | train | train | null | train |
189,243 | 3 | 155 | null | null | null | null | null | drug | Clostridium Difficile Infection Recurrence | Bacterial Infections | bronze | other | 2 | 2 | phase_4 | 4,088 | 3 | 0 | 2,019 | train | train | train | val | null | val |
189,244 | 3 | 158 | null | null | null | null | null | drug | CDI | Bacterial Infections | silver | efficacy | 1 | 1 | phase_2 | 4,088 | 3 | 0 | 2,023 | train | train | train | test | null | train |
189,245 | 3 | 160 | null | null | null | null | null | drug | Recurrent Clostridium Difficile Infection | Bacterial Infections | silver | efficacy | 1 | 1 | phase_2 | 4,088 | 7 | 0 | 2,023 | train | train | train | test | null | train |
189,246 | 3 | 161 | null | null | null | null | null | drug | C.Difficile Diarrhea | Bacterial Infections | silver | efficacy | 1 | 1 | phase_2 | 4,088 | 2 | 0 | 2,023 | val | train | train | test | null | val |
189,247 | 3 | 164 | null | null | null | null | null | drug | Chronic Hepatitis B | Blood-Borne Infections | gold | efficacy | 11 | 2 | phase_3 | 4,088 | 56 | 0 | 2,012 | test | train | test | train | null | test |
189,248 | 3 | 166 | null | null | null | null | null | drug | Eye Infections, Bacterial | Bacterial Infections | gold | efficacy | 1 | 1 | phase_4 | 4,088 | 3 | 0 | 2,012 | train | train | train | train | null | train |
189,249 | 3 | 169 | null | null | null | null | null | drug | Ocular Hypertension | Eye Diseases | silver | other | 2 | 2 | phase_4 | 4,088 | 82 | 0 | 2,020 | train | train | train | test | null | train |
189,250 | 3 | 170 | null | null | null | null | null | drug | Esophageal Squamous Cell Carcinoma | Carcinoma | silver | efficacy | 1 | 1 | phase_2 | 4,088 | 30 | 0 | 2,023 | train | train | test | test | null | train |
189,251 | 3 | 173 | null | null | null | null | null | drug | HIV | null | gold | efficacy | 20 | 2 | phase_4 | 4,088 | 114 | 0 | 2,009 | train | train | test | train | null | train |
189,252 | 3 | 175 | null | null | null | null | null | drug | Myasthenia Gravis, Generalized | Autoimmune Diseases | gold | efficacy | 1 | 1 | phase_3 | 4,088 | 4 | 0 | 2,021 | train | train | train | test | null | train |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.